Straits Times Index
3,176.51 -11.15 (-0.35%) Nikkei
37,068.35 -1,011.35 (-2.66%) Hang Seng
16,224.14 -161.73 (-0.99%) FTSE 100
7,889.50 +12.45 (+0.16%) Bitcoin USD
64,508.22 +574.46 (+0.90%) CMC Crypto 200
1,373.28 +60.65 (+4.85%)
Roche Holding AG (RHO6.F)
| Previous close | 28.01 |
| Open | 28.30 |
| Bid | 28.25 x 20000 |
| Ask | 28.67 x 20000 |
| Day's range | 28.12 - 28.60 |
| 52-week range | 27.70 - 38.40 |
| Volume | |
| Avg. volume | 123 |
| Market cap | 183.071B |
| Beta (5Y monthly) | 0.15 |
| PE ratio (TTM) | 15.29 |
| EPS (TTM) | 1.84 |
| Earnings date | N/A |
| Forward dividend & yield | 1.28 (4.57%) |
| Ex-dividend date | 14 Mar 2024 |
| 1y target est | 52.44 |
ZacksPharma Stock Roundup: JNJ's Q1 Results, LLY, ABBV, RHHBY's Successful Study Data
J&J (JNJ) posts mixed first-quarter 2024 results. Lilly's (LLY) tirzepatide meets key goals in late-stage studies for obstructive sleep apnea.
GlobeNewswireFDA approves Roche’s Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancer
Approval based on Phase III ALINA study showing Alecensa reduced the risk of disease recurrence or death by an unprecedented 76% in people with ALK-positive early-stage resected non-small cell lung cancer (NSCLC)1This approval helps address an urgent unmet need, with about half of people living with early-stage NSCLC experiencing disease recurrence following surgery, despite adjuvant chemotherapy2The National Comprehensive Cancer Network® (NCCN®) Guidelines recommend routine testing for ALK, EGF
Business WireFDA Approves Genentech's Alecensa as First Adjuvant Treatment for People With ALK-Positive Early-Stage Lung Cancer
SOUTH SAN FRANCISCO, Calif., April 18, 2024--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved Alecensa® (alectinib) for adjuvant treatment following tumor resection for patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) (tumors ≥ 4 cm or node positive), as detected by an FDA-approved test. Alecensa is now the first and only ALK inhibitor approved for people wi
